121 related articles for article (PubMed ID: 32224665)
1. Necrotizing Fasciitis in a Patient on Long-Term Intramuscular Interferon-Beta for Multiple Sclerosis: A Case Report.
McDaniel C; Trankiem C
JBJS Case Connect; 2020; 10(1):e0288. PubMed ID: 32224665
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.
Zecca C; Pavelek Z; Přikrylová K; Ghielmetti M; Beeler A; Gobbi C
Mult Scler Relat Disord; 2019 May; 30():104-109. PubMed ID: 30763907
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report.
Dalbjerg SM; Tsakiri A; Frederiksen JL
Mult Scler Relat Disord; 2016 Jul; 8():93-5. PubMed ID: 27456881
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Saida T; Itoyama Y; Tashiro K; Kira J; Hao Q;
Mult Scler; 2012 Dec; 18(12):1782-90. PubMed ID: 22492130
[TBL] [Abstract][Full Text] [Related]
6. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
Patti F; Zimatore GB; Brescia Morra V; Aguglia U; Bossio RB; Marziolo R; Valentino P; Chisari CG; Capacchione A; Zappia M;
J Neurol; 2020 Jun; 267(6):1812-1823. PubMed ID: 32140867
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study.
Cohan S; Smoot K; Kresa-Reahl K; Garland R; Yeh WS; Wu N; Watson C
Adv Ther; 2018 Nov; 35(11):1894-1904. PubMed ID: 30341505
[TBL] [Abstract][Full Text] [Related]
8. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?
Azkune Calle I; Sánchez Menoyo JL; Ruiz Ojeda J; García Moncó JC; Etxeguren Urkixo I
Neurologia; 2016 Sep; 31(7):508-9. PubMed ID: 25449964
[No Abstract] [Full Text] [Related]
9. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
10. The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.
Powell A; Myles ML; Yacyshyn E
Clin Rheumatol; 2008 Nov; 27(11):1467-8. PubMed ID: 18704546
[TBL] [Abstract][Full Text] [Related]
11. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
12. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
13. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
[TBL] [Abstract][Full Text] [Related]
14. The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
de Lemos LLP; Guerra Júnior AA; Santos M; Magliano C; Diniz I; Souza K; Pereira RG; Alvares J; Godman B; Bennie M; Zimmermann IR; Dos Santos VCC; Pretramale CA; Acurcio FA
Pharmacoeconomics; 2018 Feb; 36(2):161-173. PubMed ID: 29139001
[TBL] [Abstract][Full Text] [Related]
15. Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
Dattola V; Bonanno L; Naro A; Chillura A; Logiudice AL; Sessa E; Famà F; Quartarone A; Calabrò RS; Marino S; Russo M
Biomed Res Int; 2017; 2017():5421416. PubMed ID: 29057262
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
Hendin BA
Mult Scler Relat Disord; 2018 Nov; 26():33-36. PubMed ID: 30216756
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
[TBL] [Abstract][Full Text] [Related]
18. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
